Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Immunic (Nasdaq: IMUX), a biotechnology company focused on developing oral therapies for chronic inflammatory and autoimmune diseases, has scheduled its Q3 2024 financial results announcement and corporate update for November 7, 2024, before U.S. markets open. The company will host a webcast at 8:00 am ET on the same day. Participants can register through the company's website or via the provided Zoom link, and a replay will be available approximately one hour after the event.
Immunic (Nasdaq: IMUX), un'azienda biotecnologica focalizzata nello sviluppo di terapie orali per malattie infiammatorie croniche e autoimmuni, ha programmato l'annuncio dei risultati finanziari del Q3 2024 e un aggiornamento aziendale per il 7 novembre 2024, prima dell'apertura dei mercati statunitensi. L'azienda ospiterà un webcast alle 8:00 ET nello stesso giorno. I partecipanti possono registrarsi attraverso il sito web dell'azienda o tramite il link Zoom fornito, e una registrazione sarà disponibile circa un'ora dopo l'evento.
Immunic (Nasdaq: IMUX), una empresa biotecnológica centrada en el desarrollo de terapias orales para enfermedades autoinmunes e inflamatorias crónicas, ha programado el anuncio de sus resultados financieros del Q3 2024 y una actualización corporativa para el 7 de noviembre de 2024, antes de la apertura de los mercados en EE. UU. La compañía llevará a cabo un webcast a las 8:00 a. m. ET el mismo día. Los participantes pueden registrarse a través del sitio web de la empresa o mediante el enlace de Zoom proporcionado, y habrá una repetición disponible aproximadamente una hora después del evento.
Immunic (Nasdaq: IMUX)는 만성 염증 및 자가면역 질환에 대한 경구 요법 개발에 주력하는 생명공학 회사로, 2024년 3분기 재무 실적 발표 및 기업 업데이트를 2024년 11월 7일 미국 시장 개장 전에 예정하고 있습니다. 회사는 같은 날 오전 8시(ET)에 웹캐스트를 개최할 예정입니다. 참가자는 회사 웹사이트를 통해 또는 제공된 Zoom 링크를 통해 등록할 수 있으며, 이벤트 약 한 시간 후에 재생이 가능할 것입니다.
Immunic (Nasdaq: IMUX), une entreprise biotechnologique axée sur le développement de thérapies orales pour les maladies inflammatoires chroniques et auto-immunes, a prévu l'annonce de ses résultats financiers du T3 2024 et une mise à jour d'entreprise pour le 7 novembre 2024, avant l'ouverture des marchés aux États-Unis. L'entreprise organisera un webcast à 8h00 ET le même jour. Les participants peuvent s'inscrire via le site Web de l'entreprise ou via le lien Zoom fourni, et un replay sera disponible environ une heure après l'événement.
Immunic (Nasdaq: IMUX), ein Biotechnologieunternehmen, das sich auf die Entwicklung von oralen Therapien für chronisch entzündliche und autoimmune Krankheiten konzentriert, hat die Bekanntgabe der Q3 2024 Finanz resultate und ein Unternehmensupdate für den 7. November 2024, vor Öffnung der US-Märkte, angesetzt. Das Unternehmen wird am selben Tag um 8:00 Uhr ET ein Webcast veranstalten. Teilnehmer können sich über die Website des Unternehmens oder über den bereitgestellten Zoom-Link registrieren, und eine Wiederholung wird etwa eine Stunde nach der Veranstaltung verfügbar sein.
- None.
- None.
– Webcast to be Held at 8:00 am ET on November 7, 2024 –
To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_v2_K1Ze-QKS34X6c9W9ywg or on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; and the company's expected cash runway. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-to-announce-financial-results-for-the-third-quarter-ended-september-30-2024-and-provide-corporate-update-302288247.html
SOURCE Immunic, Inc.
FAQ
When will Immunic (IMUX) release its Q3 2024 earnings?
What time is Immunic's (IMUX) Q3 2024 earnings call?